-
公开(公告)号：US12043665B2
公开(公告)日：2024-07-23
申请号：US17306509
申请日：2021-05-03
Applicant: Genzyme Corporation
Inventor： Yunxiang Zhu , Jozsef Karman , Ronnie Wei , Canwen Jiang , Seng Cheng
IPC: C07K16/28 , A61K38/17 , A61K39/395 , A61P37/06 , C07K14/47 , C07K14/705 , C07K14/74
CPC classification number: C07K16/2803 , C07K14/47 , C07K14/70532 , C07K14/70539 , C07K2319/00
Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
-
公开(公告)号：US11028170B2
公开(公告)日：2021-06-08
申请号：US15788433
申请日：2017-10-19
Applicant: Genzyme Corporation
Inventor： Yunxiang Zhu , Jozsef Karman , Ronnie Wei , Canwen Jiang , Seng Cheng
IPC: C07K14/47 , C07K14/705 , C07K19/00 , A61K38/17 , A61K39/395 , C07K16/28 , C07K14/74
Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
-
公开(公告)号：US20210380686A1
公开(公告)日：2021-12-09
申请号：US17306509
申请日：2021-05-03
Applicant: Genzyme Corporation
Inventor： Yunxiang Zhu , Jozsef Karman , Ronnie Wei , Canwen Jiang , Seng Cheng
IPC: C07K16/28 , C07K14/74 , C07K14/47 , C07K14/705
Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
-
公开(公告)号：US20250002578A1
公开(公告)日：2025-01-02
申请号：US18741190
申请日：2024-06-12
Applicant: GENZYME CORPORATION
Inventor： Yunxiang Zhu , Jozsef Karman , Ronnie Wei , Canwen Jiang , Seng Cheng
IPC: C07K16/28 , C07K14/47 , C07K14/705 , C07K14/74
Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
-
Patent Agency Ranking
公开(公告)号：US10730936B2
公开(公告)日：2020-08-04
申请号：US15670631
申请日：2017-08-07
Applicant: GENZYME CORPORATION
Inventor： Ronnie Wei , Aaron Moulin , Magali Mathieu , Clark Pan , Sunghae Park , Huawei Qiu
IPC: A61K39/00 , A61K39/395 , C07K16/22
Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.
-
公开(公告)号：US20180030134A1
公开(公告)日：2018-02-01
申请号：US15788433
申请日：2017-10-19
Applicant: Genzyme Corporation
Inventor： Yunxiang Zhu , Jozsef Karman , Ronnie Wei , Canwen Jiang , Seng Cheng
IPC: C07K16/28 , C07K14/47 , C07K14/705 , C07K14/74
Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
-
公开(公告)号：US11505611B2
公开(公告)日：2022-11-22
申请号：US17407774
申请日：2021-08-20
Applicant: GENZYME CORPORATION
Inventor： Yves Sabbagh , Yangde Chen , William Brondyk , Huawei Qiu , Sunghae Park , Ronnie Wei , Yu Qiu , Yanfeng Zhou , Cendrine Lemoine , HyunSuk Cho
Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.
-
公开(公告)号：US20170342144A1
公开(公告)日：2017-11-30
申请号：US15670631
申请日：2017-08-07
Applicant: GENZYME CORPORATION
Inventor： Ronnie Wei , Aaron Moulin , Magali Mathieu , Clark Pan , Sunghae Park , Huawei Qiu
Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.
-
公开(公告)号：US09783604B2
公开(公告)日：2017-10-10
申请号：US14773950
申请日：2014-03-11
Applicant: GENZYME CORPORATION
Inventor： Ronnie Wei , Aaron Moulin , Magali Mathieu , Clark Pan , Sunghae Park , Huawei Qiu
IPC: C07K16/22 , A61K39/395 , C12N15/13 , A61K39/00
CPC classification number: C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92
Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
